Comparison · NCT01554397-0350032b
PET-Guided Bone Marrow-Sparing IMRT vs IMRT: Progression-free Survival
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PET-Guided Bone Marrow-Sparing IMRT vs IMRT: Progression-free Survival. Trial comparisons, record NCT01554397-0350032b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01554397-0350032b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.923 | 1 | wilson | |
| Risk in group 2 | 1 | 0.935 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0771 | 0.0653 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 1 | 1 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PET-Guided Bone Marrow-Sparing IMRT | All patients receive PET-Guided Bone Marrow-Sparing IMRT with concurrent cisplatin 40 mg/m2~Intensity Modulated Radiation Therapy (IMRT): 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks~Cisplatin: Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks | 46 | 46 | OG000 |
| Group 2 | IMRT | All patients receive IMRT with concurrent cisplatin 40 mg/m2~Intensity Modulated Radiation Therapy (IMRT): 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks~Cisplatin: Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks | 55 | 55 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Progression-free Survival
- Description
- Time from registration to first recurrence of disease or death from any cause
- Time frame
- Up to 36 Months post treatment, a total of about 38 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer
- NCT number
- NCT01554397
- Phases
- PHASE2, PHASE3
- Conditions
- Cervical Cancer
- Interventions
- PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT), Cisplatin, IMRT
- Lead sponsor
- University of California, San Diego
- Results first posted
- 2024-11-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01554397?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01554397-0350032b